Published in Clin Infect Dis on January 24, 2007
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant (2008) 0.88
Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol (2011) 0.83
Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety. Mediterr J Hematol Infect Dis (2016) 0.83
Assessment of antibody titers and immunity to Hepatitis B in children receiving chemotherapy. Iran J Ped Hematol Oncol (2012) 0.82
Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother (2015) 0.76
Pneumococcal vaccination of children after hematopoietic stem cell transplantation: timing is crucial. Clin Infect Dis (2007) 0.75
Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review. Hum Vaccin Immunother (2015) 0.75
Reassessing the cutoff level for poliovirus antibody in patients after successful chemotherapy for leukemia or hematopoietic stem cell transplantation. Clin Infect Dis (2007) 0.75
Reimmunization after therapy for childhood cancer. Clin Infect Dis (2007) 0.75
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol (2016) 0.75
Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet (2012) 2.98
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med (2010) 1.99
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child (2011) 1.91
Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis (2004) 1.91
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerg Infect Dis (2010) 1.77
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis (2003) 1.76
Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods (2004) 1.74
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed (2010) 1.69
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol (2004) 1.59
Added value of PCR-testing for confirmation of invasive meningococcal disease in England. J Infect (2013) 1.58
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis (2005) 1.56
Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine (2012) 1.54
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine (2013) 1.49
An overview of global GBS epidemiology. Vaccine (2013) 1.47
Risk factors for late onset gram-negative infections: a case-control study. Arch Dis Child Fetal Neonatal Ed (2010) 1.47
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Haemophilus influenzae type b vaccine--booster campaign. BMJ (2003) 1.46
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine (2009) 1.44
A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis (2008) 1.44
Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child (2012) 1.42
Long-term immunological follow-up of children with haemophilus influenzae serotype b vaccine failure in the United Kingdom. Clin Infect Dis (2009) 1.42
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood (2010) 1.40
Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Pediatr Infect Dis J (2015) 1.38
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines (2011) 1.35
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis (2007) 1.30
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med (2008) 1.30
Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis (2008) 1.26
Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J (2005) 1.24
Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis (2007) 1.23
Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol (2004) 1.22
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther (2011) 1.20
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine (2012) 1.19
Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol (2004) 1.19
Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol (2008) 1.19
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol (2011) 1.18
Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One (2011) 1.16
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis (2013) 1.13
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog (2012) 1.10
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol (2008) 1.10
Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol (2010) 1.09
Use of pneumococcal polysaccharide vaccine in children: what is the evidence? Curr Opin Infect Dis (2012) 1.09
Neisseria lactamica protects against experimental meningococcal infection. Infect Immun (2002) 1.09
Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis (2014) 1.08
Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis (2009) 1.08
Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis (2011) 1.07
Improving the outcome of neonatal meningitis. Curr Opin Infect Dis (2009) 1.06
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol (2009) 1.06
Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine (2003) 1.05
Immunity to tetanus and diphtheria in the UK in 2009. Vaccine (2012) 1.05
Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One (2013) 1.04
Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis (2011) 1.04
Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol (2006) 1.02
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine (2011) 1.02
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine (2006) 1.02
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis (2016) 1.00
Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine (2010) 0.98
Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines (2004) 0.98
Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine. Clin Vaccine Immunol (2006) 0.97
A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2008) 0.97
Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol (2007) 0.97
Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol (2007) 0.97
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol (2004) 0.97
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol (2004) 0.96
Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J Immunol (2003) 0.96
Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin (2007) 0.95
Improving antibiotic prescribing in neonatal units: time to act. Arch Dis Child Fetal Neonatal Ed (2010) 0.95
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol (2012) 0.95
Evolving meningococcal immunization strategies. Expert Rev Vaccines (2014) 0.94